RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
基本信息
- 批准号:10640898
- 负责人:
- 金额:$ 52.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffinityAmyotrophic Lateral SclerosisAttenuatedAutopsyAuxinsAxotomyBindingBiological AssayCRISPR interferenceCRISPR-mediated transcriptional activationCell LineCell NucleusCellsCellular AssayChemistryCollaborationsComplexCustomCytoplasmDNADataDefectDiffuseDiffusionDiseaseDominant-Negative MutationDoseDrosophila genusEnergy consumptionExclusionFrontotemporal DementiaIn VitroInjectionsLabelLibrariesLinkMass Spectrum AnalysisMediatingMessenger RNAMicroscopyModelingMolecularMolecular ChaperonesMusMutationNerve CrushNerve DegenerationNeuronsNuclearNuclear ExportNuclear PoreNuclear Pore ComplexNuclear RNAOligonucleotidesPathogenesisPathway interactionsPatientsPermeabilityPhotobleachingPilot ProjectsPlayPreclinical TestingProteinsRNARNA BindingRNA ProcessingRNA SplicingRNA StabilityRNA-Binding ProteinsRegulationRoleSmall Interfering RNASpliceosomesTemperatureTestingTherapeuticTherapeutic AgentsTissuesTreatment EfficacyUridineValidationanalogblood-brain barrier crossingdrug developmentexportin 1 proteinfamilial amyotrophic lateral sclerosisfrontotemporal lobar dementia amyotrophic lateral sclerosishelicasein vivoknock-downmRNA Exportmutantneuropathologyneuroprotectionnovel strategiesnucleocytoplasmic transportnucleoside analogpre-clinicalpreventprotein TDP-43receptorsciatic nervesubcutaneoustherapeutic evaluationtherapeutic targettranscriptome sequencing
项目摘要
TAR DNA-binding protein-43 (TDP-43) is an essential DNA/RNA-binding protein that plays a major role in RNA
processing and stability. Although predominantly nuclear in localization, over 95% of amyotrophic lateral
sclerosis (ALS) cases and up to half of frontotemporal dementia (FTD) cases show mislocalization of TDP-43
to the cytoplasm. Substantial evidence links TDP-43 mislocalization to the pathogenesis of neurodegeneration
in ALS/FTD, and TDP-43 mutations have been identified in subset of familial ALS cases, further supporting a
primary role for TDP-43 disruption in disease. However, the cause of TDP-43 nuclear clearance in ALS/FTD
remains unknown. A major barrier has been lack of understanding of the mechanism of TDP-43 nuclear export.
Until recently, TDP-43 was thought to be a cargo of the nuclear export receptor, exportin-1 (XPO1). However,
multiple recent studies demonstrate that XPO1 does not bind TDP-43 or mediate its export. Alternative export
mechanisms may include passive diffusion from the nucleus, or active co-export with RNA, such as via the
NXF1/TREX mRNA export complex. Our preliminary data show that TDP-43 nuclear export is ATP- and RNA-
dependent, but the energy may be required upstream of the pore, for TDP-43 intranuclear mobility, rather than
translocation across the nuclear pore complex (NPC). Indeed, a permeabilized cell assay suggests that, once
displaced from nuclear RNA, TDP-43 likely diffuses out of the nucleus. Moreover, studies in an NXF1 auxin-
inducible degron (AID) cell line suggest that the bulk mRNA pathway is not required for TDP-43 export. Based
on these data, we hypothesize that ATP-dependent nuclear tethering of TDP-43, most likely to nuclear RNA,
critically dictates the rate at which it diffuses into the cytoplasm. In the proposed studies, we will perform an
arrayed CRISPRi and CRISPRa screen of a targeted library to determine the mechanism of energy-dependent
nuclear tethering of TDP-43. Hits will be validated in nuclear transport and photobleaching assays, and also
evaluated in ALS/FTD patient tissue. We will then combine high content microscopy with nucleocytoplasmic
transport assays, including a newly developed permeabilized cell export assay, to confirm the mechanism of
TDP-43 translocation across the nuclear pore during export. Additional AID cell lines and knockdown studies
will be used to definitively exclude a role for the mRNA export pathway. Finally, we will test the therapeutic
efficacy of a novel approach to promote TDP-43 nuclear retention, identified during our preliminary studies.
Testing will include TDP-43 mutant Drosophila (in collaboration with the Daniela Zarnescu lab), TDP-43 mutant
iNeurons, and mouse sciatic nerve axotomy, to determine if we can promote TDP-43 nuclear retention in vivo,
and whether this strategy will attenuate molecular and neuropathologic features of TDP-43 proteinopathy.
These studies will enable a precise mechanistic understanding of the mechanism and regulation of TDP-43
nuclear export, and advance preclinical testing of a candidate strategy to promote TDP-43 nuclear retention.
TAR DNA结合蛋白-43(TDP-43)是必不可少的DNA/RNA结合蛋白,在RNA中起主要作用
处理和稳定性。虽然主要是核定核的,但超过95%的肌萎缩性侧面
硬化病(ALS)病例和多达一半的额颞痴呆(FTD)病例显示TDP-43的静置错误
到细胞质。大量证据将TDP-43错误定位与神经退行性的发病机理联系起来
在ALS/FTD中,在家族性ALS病例的子集中已经确定了TDP-43突变,进一步支持A
TDP-43破坏在疾病中的主要作用。但是,ALS/FTD中TDP-43核清除率的原因
仍然未知。主要的障碍是缺乏对TDP-43核出口机理的理解。
直到最近,TDP-43被认为是核出口受体Exportin-1(XPO1)的货物。然而,
最近的多项研究表明,XPO1不结合TDP-43或介导其出口。替代出口
机制可能包括从细胞核中被动扩散,或与RNA共同出口,例如通过
NXF1/Trex mRNA导出复合物。我们的初步数据表明,TDP-43核输出是ATP和RNA-
依赖性,但可能需要孔的上游,对于TDP-43核内迁移率,而不是
跨核孔复合物(NPC)的易位。确实,透化细胞测定法表明,一次
TDP-43从核RNA中移位,可能会从细胞核中扩散。此外,对NXF1生长素的研究
可诱导的degron(AID)细胞系表明TDP-43导出不需要大量mRNA途径。基于
在这些数据上,我们假设TDP-43的ATP依赖性核束缚,最有可能是核RNA,
批判性地决定了它扩散到细胞质中的速率。在拟议的研究中,我们将执行
有针对性库的Arryed Crispri和Crispra屏幕,以确定能量依赖的机理
TDP-43的核束缚。点击将在核运输和光漂白测定中得到验证,也将
在ALS/FTD患者组织中进行评估。然后,我们将将高含量显微镜与核细胞质结合在一起
运输分析,包括新开发的通透性细胞出口测定法,以确认
出口期间,TDP-43跨核孔的易位。其他援助细胞线和敲低研究
将用于明确排除mRNA输出途径的作用。最后,我们将测试治疗性
在我们的初步研究中确定的一种新型方法来促进TDP-43核保留率的功效。
测试将包括TDP-43突变果蝇(与Daniela Zarnescu实验室合作),TDP-43突变体
无神经元和小鼠坐骨神经轴切开术,以确定我们是否可以促进TDP-43体内核保留率,
以及该策略是否会减弱TDP-43蛋白质病的分子和神经病理特征。
这些研究将使对TDP-43的机制和调节的机理和调节有了精确的机械理解
核出口,并预先对促进TDP-43核保留的候选策略进行临床前测试。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nuclear RNA binding regulates TDP-43 nuclear localization and passive nuclear export.
- DOI:10.1016/j.celrep.2022.111106
- 发表时间:2022-07-19
- 期刊:
- 影响因子:8.8
- 作者:Duan, Lauren;Zaepfel, Benjamin L.;Aksenova, Vasilisa;Dasso, Mary;Rothstein, Jeffrey D.;Kalab, Petr;Hayes, Lindsey R.
- 通讯作者:Hayes, Lindsey R.
RNA-mediated ribonucleoprotein assembly controls TDP-43 nuclear retention.
RNA 介导的核糖核蛋白组装控制 TDP-43 核保留。
- DOI:10.1371/journal.pbio.3002527
- 发表时间:2024
- 期刊:
- 影响因子:9.8
- 作者:DosPassos,PatriciaM;Hemamali,ErandikaH;Mamede,LohanyD;Hayes,LindseyR;Ayala,YunaM
- 通讯作者:Ayala,YunaM
Order from chaos: Using CSF proteomics to predict ALS progression.
- DOI:10.1002/acn3.51910
- 发表时间:2023-12
- 期刊:
- 影响因子:5.3
- 作者:Yang, Xiuli;Hayes, Lindsey R.
- 通讯作者:Hayes, Lindsey R.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lindsey Renae Hayes其他文献
Lindsey Renae Hayes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lindsey Renae Hayes', 18)}}的其他基金
Development of TDP-43 nuclear targeting aptamers for ALS/FTD
用于 ALS/FTD 的 TDP-43 核靶向适体的开发
- 批准号:
10427644 - 财政年份:2022
- 资助金额:
$ 52.01万 - 项目类别:
Development of TDP-43 nuclear targeting aptamers for ALS/FTD
用于 ALS/FTD 的 TDP-43 核靶向适体的开发
- 批准号:
10558610 - 财政年份:2022
- 资助金额:
$ 52.01万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10455671 - 财政年份:2021
- 资助金额:
$ 52.01万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10285495 - 财政年份:2021
- 资助金额:
$ 52.01万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
10237182 - 财政年份:2017
- 资助金额:
$ 52.01万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9431708 - 财政年份:2017
- 资助金额:
$ 52.01万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9751978 - 财政年份:2017
- 资助金额:
$ 52.01万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9980498 - 财政年份:2017
- 资助金额:
$ 52.01万 - 项目类别:
相似国自然基金
磷脂结合蛋白Annexin A11相变在肌萎缩性脊髓侧索硬化症中的作用及机制研究
- 批准号:82101509
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
磷脂结合蛋白Annexin A11相变在肌萎缩性脊髓侧索硬化症中的作用及机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
C9orf72 多聚重复蛋白对miRNA生成和功能影响及其在ALS/FTD发病机制中的作用研究
- 批准号:81701261
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
线粒体蛋白CHCHD10稳定突触的作用及机制研究
- 批准号:31701036
- 批准年份:2017
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
伴TBK1突变肌萎缩性脊髓侧索硬化症中RIPK1活化的意义及机制研究
- 批准号:31701207
- 批准年份:2017
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 52.01万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10455671 - 财政年份:2021
- 资助金额:
$ 52.01万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10285495 - 财政年份:2021
- 资助金额:
$ 52.01万 - 项目类别:
Novel Riluzole Derivatives for Alzheimer's Disease
治疗阿尔茨海默病的新型利鲁唑衍生物
- 批准号:
9979211 - 财政年份:2020
- 资助金额:
$ 52.01万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
10237182 - 财政年份:2017
- 资助金额:
$ 52.01万 - 项目类别: